Investor Relations

Overview

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients’ lives. BioXcel Therapeutics employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines while aiming to increase the possibility of success. Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. We believe that this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.

 

Latest Presentation

Events

Latest Financial Results

Show all

Latest Annual Filing

Form Filing date Description View
10-K

Annual report which provides a comprehensive overview of the company for the past year

View HTML EX-101.INS - EX-101.INS
      Sign Up for Email Alerts
Receive updates straight into your inbox

BioXcel Therapeutics, Inc.


Data Provided by Refinitiv.

Price
Change
Volume
52 Week High
52 Week Low

About BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the acute treatment of agitation associated with Alzheimer’s disease and as an adjunctive treatment for Major Depressive Disorder, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Investor Relations and Media Contacts

Corporate

BioXcel Therapeutics
Erik Kopp

Investor Relations

FTI Consulting

Media

FTI Consulting
Helen O'Gorman
T: 718-408-0800
helen.ogorman@fticonsulting.com